Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Cizolirtine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.48 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.48 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.48 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.48 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.48 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.48 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.48 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.43 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 8/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cizolirtine SCHEMBL2791717 | 1.00 | LMNA (0.65) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| SCHEMBL5924572 | 0.87 | LMNA (0.62) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| Citric Acid SCHEMBL5185028 | 0.87 | KDM4E (0.48) | LMNAKDM4ECYP2D6SLC6A4SLC6A3 | |
| Diphenhydramine SCHEMBL322306 | 0.86 | LMNA (0.80) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| Cizolirtine SCHEMBL2776433 | 0.86 | SLC6A2 (0.65) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| Cizolirtine SCHEMBL290138 | 0.86 | SLC6A2 (0.65) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| Cizolirtine SCHEMBL5186750 | 0.86 | SLC6A2 (0.65) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| Citric Acid SCHEMBL4902057 | 0.85 | LMNA (0.50) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| Diphenhydramine SCHEMBL5678067 | 0.85 | LMNA (0.79) | LMNAKDM4ECYP2D6CHRM2SLC6A2 | |
| Diphenhydramine SCHEMBL7914760 | 0.85 | LMNA (0.79) | LMNAKDM4ECYP2D6CHRM2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| EP-1786419-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1786420-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1784178-A1 | ARYL (OR HETEROARYL) AZOLYLCARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-16 | — | — | EP | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| EP-1746986-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | claimed |
| WO-2005097192-A9 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | ESTEVE LABOR DR (ES) | 2007-01-18 | — | — | WO | claimed |
| EP-1740174-A1 | DERIVATIVES OF ARYL(OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF ENURESIS | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-10 | — | — | EP | claimed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | claimed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| US-20050222135-A1 | Active substance combination | LABORATIONS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| WO-2005067925-A1 | DERIVATIVES OF ARYL(OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF ENURESIS | LABORATORIOS DR. ESTEVE S.A. (ES) | 2005-07-28 | — | — | WO | claimed |
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-07-22 | — | — | US | claimed |
| EP-1103243-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | ESTEVE LABOR DR (ES) | 2004-01-07 | — | — | EP | claimed |
| EP-1086682-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION | ESTEVE LABOR DR (ES) | 2003-04-16 | — | — | EP | claimed |
| US-6518295-B1 | Such as anxiety, depression, schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, and locomotive disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-1086682-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222135-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | SLC6A2 140/4885OPRM1 1/4885HRH1 1541/4885 |
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | AADAC, AHR, ABAT | SLC6A2 1099/4885OPRM1 494/4885HRH1 155/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | SLC6A2 1741/4885OPRM1 133/4885HRH1 1125/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | SLC6A2 299/4885OPRM1 7/4885HRH1 1336/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | SLC6A2 690/4885OPRM1 122/4885HRH1 1155/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | SLC6A2 140/4885OPRM1 1/4885HRH1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.